文献速递儿科与产科急症

妊娠期接种COVID-19疫苗与不良围产期结局的关系

Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes.
PubMed 文献 · JAMA · 2022-01-01
一句话结论基于加拿大安大略省人群的回顾性队列研究显示,妊娠期接种COVID-19疫苗(主要为mRNA疫苗、多在第二和第三孕期接种)与不良围产期结局风险增加无显著关联。

该研究基于加拿大安大略省出生登记与省级COVID-19免疫数据库链接的人群回顾性队列,纳入2020年12月14日至2021年9月30日所有分娩者共97 590人,比较妊娠期接种、妊娠后接种及从未接种COVID-19疫苗者的围产期结局。采用逆概率治疗加权调整混杂后发现,与妊娠后接种者相比,妊娠期接种者产后出血、绒毛膜羊膜炎风险无显著增加,剖宫产、新生儿重症监护病房入住及5分钟Apgar评分低的风险未升高。与从未接种者比较结果定性相似。结论认为妊娠期接种COVID-19疫苗与不良围产期结局风险增加无显著关联,但研究解读需考虑妊娠期所接种疫苗主要为mRNA疫苗且多在第二、第三孕期接种。

要点

  • 妊娠期接种COVID-19疫苗者产后出血发生率为3.0%,妊娠后接种者为3.0%,aRD -0.28/100人(95%CI -0.59至0.03),aRR 0.91(95%CI 0.82-1.02),风险无显著增加。
  • 妊娠期接种者剖宫产率为30.8%,妊娠后接种者为32.2%,aRD -2.73/100人(95%CI -3.59至-1.88),aRR 0.92(95%CI 0.89-0.95)。
  • 妊娠期接种者新生儿重症监护病房入住率为11.0%,妊娠后接种者为13.3%,aRD -1.89/100名新生儿(95%CI -2.49至-1.30),aRR 0.85(95%CI 0.80-0.90)。
  • 妊娠期接种者新生儿5分钟Apgar评分低(<7)发生率为1.8%,妊娠后接种者为2.0%,aRD -0.31/100名新生儿(95%CI -0.56至-0.06),aRR 0.84(95%CI 0.73-0.97)。
  • 与从未接种COVID-19疫苗者(n=30 115)比较,结果定性相似;妊娠期接种者中63.6%在第三孕期接种第一剂,99.8%接种mRNA疫苗。

适用人群与场景

  • 加拿大安大略省2020年12月14日至2021年9月30日所有分娩者,共97 590人,平均(SD)年龄31.9(4.9)岁。
  • 妊娠期接种组22 660人(23%),其中63.6%在第三孕期接种第一剂,99.8%接种mRNA疫苗;妊娠后接种组44 815人;从未接种组30 115人。

研究设计与关键结果

  • 研究类型:基于人群的回顾性队列研究,使用出生登记与省级COVID-19免疫数据库链接,采用逆概率治疗加权调整混杂,线性回归和稳健泊松回归分别生成调整风险差(aRD)和风险比(aRR)。
  • 妊娠期接种 vs 妊娠后接种:产后出血发生率3.0% vs 3.0%,aRD -0.28/100人(95%CI -0.59至0.03),aRR 0.91(95%CI 0.82-1.02);绒毛膜羊膜炎0.5% vs 0.5%,aRD -0.04/100人(95%CI -0.17至0.09),aRR 0.92(95%CI 0.70-1.21)。
  • 妊娠期接种 vs 妊娠后接种:剖宫产30.8% vs 32.2%,aRD -2.73/100人(95%CI -3.59至-1.88),aRR 0.92(95%CI 0.89-0.95);新生儿重症监护病房入住11.0% vs 13.3%,aRD -1.89/100名新生儿(95%CI -2.49至-1.30),aRR 0.85(95%CI 0.80-0.90)。
  • 妊娠期接种 vs 妊娠后接种:新生儿5分钟Apgar评分低(<7)1.8% vs 2.0%,aRD -0.31/100名新生儿(95%CI -0.56至-0.06),aRR 0.84(95%CI 0.73-0.97)。
  • 与从未接种COVID-19疫苗者(n=30 115)比较,结果定性相似。

证据类型、等级与局限

  • 证据类型:基于人群的回顾性队列研究。
  • 局限:研究解读需考虑妊娠期所接种疫苗主要为mRNA疫苗且多在第二和第三孕期接种。

对床旁实践的改变

  • 作者认为,妊娠期接种COVID-19疫苗(主要为mRNA疫苗、多在第二和第三孕期接种)与不良围产期结局风险增加无显著关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: There is limited comparative epidemiological evidence on outcomes associated with COVID-19 vaccination during pregnancy; monitoring pregnancy outcomes in large populations is required.

OBJECTIVE: To evaluate peripartum outcomes following COVID-19 vaccination during pregnancy.

DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study in Ontario, Canada, using a birth registry linked with the provincial COVID-19 immunization database. All births between December 14, 2020, and September 30, 2021, were included.

EXPOSURES: COVID-19 vaccination during pregnancy, COVID-19 vaccination after pregnancy, and no vaccination.

MAIN OUTCOMES AND MEASURES: Postpartum hemorrhage, chorioamnionitis, cesarean delivery (overall and emergency cesarean delivery), admission to neonatal intensive care unit (NICU), and low newborn 5-minute Apgar score (<7). Linear and robust Poisson regression was used to generate adjusted risk differences (aRDs) and risk ratios (aRRs), respectively, comparing cumulative incidence of outcomes in those who received COVID-19 vaccination during pregnancy with those vaccinated after pregnancy and those with no record of COVID-19 vaccination at any point. Inverse probability of treatment weights were used to adjust for confounding.

RESULTS: Among 97 590 individuals (mean [SD] age, 31.9 [4.9] years), 22 660 (23%) received at least 1 dose of COVID-19 vaccine during pregnancy (63.6% received dose 1 in the third trimester; 99.8% received an mRNA vaccine). Comparing those vaccinated during vs after pregnancy (n = 44 815), there were no significantly increased risks of postpartum hemorrhage (incidence: 3.0% vs 3.0%; aRD, -0.28 per 100 individuals [95% CI, -0.59 to 0.03]; aRR, 0.91 [95% CI, 0.82-1.02]), chorioamnionitis (0.5% vs 0.5%; aRD, -0.04 per 100 individuals [95% CI, -0.17 to 0.09]; aRR, 0.92 [95% CI, 0.70-1.21]), cesarean delivery (30.8% vs 32.2%; aRD, -2.73 per 100 individuals [95% CI, -3.59 to -1.88]; aRR, 0.92 [95% CI, 0.89-0.95]), NICU admission (11.0% vs 13.3%; aRD, -1.89 per 100 newborns [95% CI, -2.49 to -1.30]; aRR, 0.85 [95% CI, 0.80-0.90]), or low Apgar score (1.8% vs 2.0%; aRD, -0.31 per 100 newborns [95% CI, -0.56 to -0.06]; aRR, 0.84 [95% CI, 0.73-0.97]). Findings were qualitatively similar when compared with individuals who did not receive COVID-19 vaccination at any point (n = 30 115).

CONCLUSIONS AND RELEVANCE: In this population-based cohort study in Ontario, Canada, COVID-19 vaccination during pregnancy, compared with vaccination after pregnancy and with no vaccination, was not significantly associated with increased risk of adverse peripartum outcomes. Study interpretation should consider that the vaccinations received during pregnancy were primarily mRNA vaccines administered in the second and third trimester.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Fell DB, Dhinsa T, Alton GD, et al. Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. JAMA. 2022. PMID: 35323842. doi:10.1001/jama.2022.4255

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。